1 day ago
1
koto_feja/E+ via Getty Images
Shares of Summit Therapeutics (NASDAQ:SMMT) rose in the premarket on Friday after the U.S. biotech said its lead asset, ivonescimab, developed with its Chinese partner Akeso (OTCPK:AKESF), reached the main goal as part of a combination regimen
English (US) ·